Onconova Therapeutics, Inc. (ONTX) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Revenues			0.2	0.2	0.2	0.2	0.2	0.2
Revenue growth			-0.4%	-4.2%	-3.8%	-2.2%	11.3%	17.4%
Cost of goods sold			0.0	0.0	0.0	0.0	0.0	0.0
Gross profit			0.2	0.2	0.2	0.2	0.2	0.2
Gross margin			100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Selling, general and administrative [+]			8.5	8.7	9.4	9.4	9.1	9.0
General and administrative			8.5	8.7	9.4	9.4	9.1	9.0
Research and development			9.4	7.5	7.4	7.3	10.1	12.5
EBITDA [+]			-17.6	-16.0	-16.5	-16.5	-19.0	-21.3
EBITDA growth			-7.0%	-24.8%	-31.0%	-34.0%	-22.4%	-8.7%
EBITDA margin			-7806.2%	-7075.7%	-7308.0%	-7292.9%	-8358.6%	-9007.2%
Depreciation and amortization			0.0	0.0	0.0	0.0	0.0	0.0
EBIT [+]			-17.7	-16.0	-16.5	-16.5	-19.0	-21.3
EBIT growth			-7.0%	-24.8%	-31.0%	-34.0%	-22.4%	-8.7%
EBIT margin			-7812.4%	-7081.9%	-7314.2%	-7299.1%	-8364.8%	-9013.6%
Other income (expense), net [+]			1.5	-0.2	0.4	0.3	-6.2	-3.9
Change in fair value of warrants							0.2	-0.3
Other			0.3	0.1	0.0	0.0	0.0	0.0
Pre-tax income			-16.2	-16.2	-16.2	-16.2	-25.2	-25.2
Income taxes			0.0	0.0	0.0	0.0	0.0	0.0
Tax rate			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income			-17.3	-15.4	-15.6	-16.2	-18.8	-21.6
Net margin			-7658.4%	-6797.8%	-6889.4%	-7151.8%	-8294.3%	-9159.3%

Basic EPS [+]			($0.87)	($0.82)	($0.90)	($1.02)	($1.30)	($1.60)
Growth			-33.0%	-48.5%	-55.2%	98.5%	162.8%	236.6%
Diluted EPS [+]			($0.87)	($0.82)	($0.90)	($1.02)	($1.30)	($1.60)
Growth			-33.0%	-48.5%	-55.2%	98.5%	162.8%	236.6%

Shares outstanding (basic) [+]			19.9	18.7	17.4	15.8	14.5	13.5
Growth			37.2%	38.0%	40.2%	-67.6%	-70.7%	-71.9%
Shares outstanding (diluted) [+]			19.9	18.7	17.4	15.8	14.5	13.5
Growth			37.2%	38.0%	40.2%	-67.6%	-70.7%	-71.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.